Taxus express

Manufactured by Boston Scientific

Sourced in United States

The TAXUS Express is a medical device used in the treatment of coronary artery disease. It is a drug-eluting stent that is designed to be implanted in the artery to help keep it open and improve blood flow. The device consists of a metallic stent coated with the drug paclitaxel, which is intended to prevent the artery from re-narrowing after the stent is implanted.

Automatically generated - may contain errors

Lab products found in correlation

Promus element, by Boston Scientific (1 mentions) Xience prime, by Abbott (1 mentions) Xience, by Abbott (1 mentions) Cypher select, by Cordis (1 mentions) Promus, by Boston Scientific (1 mentions)

4 protocols using taxus express

Coronary Angiography and DES Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols

Coronary angiography was performed with standard techniques. Quantitative coronary angiographic analyses were performed in optimal projections using the Cardiovascular Angiography Analysis System II (Pie Medical Imaging, Maastricht, The Netherlands) by an experienced analyst who was unaware of the clinical status of the patients.
Before the procedure, aspirin and 300~600 mg of clopidogrel were administered to all patients. Heparin was administered during the procedure according to standard practice. All patients were recommended to maintain lifelong doses of aspirin (100mg/day) and clopidogrel (75mg/day) for at least 1 year after the index PCI. Patients received DES treatment using sirolimus-eluting stents (Cypher, Cordis Corporation, Johnson & Johnson, Warren, NJ, USA), paclitaxel-eluting stents (TAXUS Express or Liberté, Boston Scientific, Natick, MA, USA; Coroflex Please, B. Braun, Germany), everolimus-eluting stents (Promus Element, Boston Scientific; Xience Prime, Abbott Vascular, Santa Clara, CA, USA), and zotarolimus-eluting stents (Endeavor, Medtronic Vascular, Minneapolis, MN, USA).

Park S.J., Lim H.S., Sheen S.S., Yang H.M., Seo K.W., Choi S.Y., Choi B.J., Yoon M.H, & Tahk S.J. (2018). Impact of body fat distribution on long-term clinical outcomes after drug-eluting stent implantation. PLoS ONE, 13(5), e0197991.

+ Open protocol

+ Expand

Coronary Stent Restenosis Patterns

Check if the same lab product or an alternative is used in the 5 most similar protocols

A total of 66 ISR lesions were identified in 41 consecutive patients enrolled in this study. We found 44 ISR within G1 DES: 21 sirolimus-eluting stents (SES) (Cypher SELECT, Cordis, Miami Lakes, FL, USA) and 23 paclitaxel-eluting stents (PES) (Taxus EXPRESS and Liberté, Boston Scientific, Natick, MA, USA). We also identified 22 ISR lesions in G2 DES: of which 11 everolimus-eluting stents (EES) (9 Xience, Abbott Vascular, Santa Clara, CA, USA; and 2 Promus, Boston Scientific, Natick, MA, USA) 10 zotarolimus-eluting stents (ZES) (Resolute, Medtronic, Santa Rosa, CA, USA) and 1 biolimus-eluting stent (BES) (BioMatrix Flex, Biosensors Inc, Newport Beach, CA, USA) (Fig. 3). Coronary angiography was clinically driven in 58.2% of cases and electively scheduled in the remaining. Only 5 lesions (7.6%) required balloon pre-dilatation before OCT pullback.Fig. 3

Schematic view of enrolled stents, according to generation, eluted drug and brand. For acronyms see “Results” chapter.

Kilickesmez K., Dall'Ara G., Rama-Merchan J.C., Ghione M., Mattesini A., Vinues C.M., Konstantinidis N., Pighi M., Estevez-Loureiro R., Zivelonghi C., Lindsay A.C., Secco G.G., Foin N., De Silva R, & Di Mario C. (2014). Optical coherence tomography characteristics of in-stent restenosis are different between first and second generation drug eluting stents. International Journal of Cardiology. Heart & Vessels, 3, 68-74.

+ Open protocol

+ Expand

Comparison of DES and PCB Interventions

Check if the same lab product or an alternative is used in the 5 most similar protocols

All patients were treated with acetylsalicylic acid 200 mg and loading dose of clopidogrel 300 mg before the procedure followed by maintenance clopidogrel 75 mg daily for at least 12-months in DES group and for 6 weeks and for extended periods thereafter at the physician's discretion in PCB group. DESs for all implanted lesions were Cypher™ (Cordis, Johnson & Johnson Co., New Jersey, FL, USA), Taxus Express™ (Boston Scientific, Natick, MA, USA) and Endeavor™ (Medtronic Co., Minneapolis, MN, USA). For PCB treatment, the standard balloon was shorter than the intended PCB size, and the PCB (SeQuent Please®, PCB catheter, B. Braun, Melsungen, Germany) was inflated at nominal pressure for 60 seconds. Post-dilation was not performed in all PCB cases. Coronary angiographies before and after the procedure were analyzed using the Cardiovascular Angiography Analysis System (CAAS 5.10, Pie Medical Imaging B.V., Maastricht, the Netherlands) by an independent investigator, who was blinded to clinical presentations.

Her A.Y., Cho K.I., Singh G.B., Garg S., Kim Y.H., Koo B.K, & Shin E.S. (2016). A Comparison of Peri-Procedural Myocardial Infarction between Paclitaxel-Coated Balloon and Drug-Eluting Stent on De Novo Coronary Lesions. Yonsei Medical Journal, 58(1), 99-104.

+ Open protocol

+ Expand

Randomized CABG vs PCI for 3VD/LMCAD

Check if the same lab product or an alternative is used in the 5 most similar protocols

The design of the SYNTAX trial and its primary and final 5-year results have been previously reported. 16 In brief, the SYNTAX trial was a prospective, international, multicentre, randomized controlled trial conducted across 85 centres in Europe and the USA. Based on clinical judgement and the consensus of a Heart Team (consisting of a cardiothoracic surgeon and interventional cardiologist at each site), patients with de novo 3VD and/or LMCAD who were anticipated to achieve clinical equipoise between CABG and PCI were enrolled and randomized in a 1:1 fashion either to receive CABG (n = 897) or PCI (n = 903) with TAXUS Express paclitaxel-drug eluting stents (PES) (Boston Scientific Corporation, Marlborough, MA, USA). The SYNTAX trial (NCT00114972) completed patient follow-up at 5 years, and the SYNTAXES study (NCT03417050) has evaluated vital status between 5 and 10 years. 15 These trials were approved by the ethics committees at each investigating centre, and all patients provided their written informed consent prior to participation in the SYNTAX trial.

Takahashi K., Thuijs D.J.F.M., Gao C., Ono M., Holmes D.R., Mack M.J., Morice M.C., Mohr F.W., Curzen N., Davierwala P.M., Milojevic M., Dawkins K.D., Wykrzykowska J.J., de Winter R.J., McEvoy J.W., Onuma Y., Head S.J., Kappetein A.P, & Serruys P.W. (2022). Ten-year all-cause mortality according to smoking status in patients with severe coronary artery disease undergoing surgical or percutaneous revascularization. European journal of preventive cardiology, 29(2).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!